Literature DB >> 21841816

Chimeric flagellin expressed by Salmonella typhimurium induces an ESAT-6-specific Th1-type immune response and CTL effects following intranasal immunization.

Hui Zhang1, Liu Liu, Ke Wen, Jinlin Huang, Shizhong Geng, Junsong Shen, Zhiming Pan, Xinan Jiao.   

Abstract

The flagellin component FliC of Salmonella typhimurium is capable of activating the innate immune system via specific interactions with TLR5 and can also act as a carrier of foreign antigen to elicit antigen-specific immune responses. Thus, we constructed an attenuated Salmonella strain SL5928(fliC/esat) expressing chimeric flagellin that contained the ESAT-6 antigen coding sequence of Mycobacterium tuberculosis inserted into the highly variable region of the Salmonella flagellin coding gene fliC(i). The chimeric flagellin functioned normally, as demonstrated using a flagella swarming assay and electron microscopy. To analyze the effects of chimeric flagellin, the cell-mediated immune response and cytotoxic T lymphocyte (CTL) effects specific for ESAT-6 antigen were tested after intranasal immunization of mice with flagellated Salmonella SL5928(fliC/esat). The results showed that SL5928(fliC/esat) intranasal immunization can strongly elicit an ESAT-6-specific T helper (Th) 1-type immune response in mucosal lymphoid tissues, such as nasopharynx-associated lymph nodes, lung and Peyer's patches, and a Th1/Th2 response was elicited in spleen and mesenteric lymph nodes. Furthermore, intranasal immunization of SL5928(fliC/esat) produced efficient CTL effects, as demonstrated using a 5- and 6-carboxyfluorescein diacetate succinimidyl ester (CFSE) assay. Thus, our study revealed that Salmonella flagellin acts as a carrier for foreign antigen and triggers strong Th1 and CTL responses during intranasal immunization. Chimeric flagellin is potentially an effective strategy for the development of novel vaccines against tuberculosis in humans and animals.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21841816      PMCID: PMC4012927          DOI: 10.1038/cmi.2011.24

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  31 in total

1.  Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus.

Authors:  Sung Ho Jeon; Tamar Ben-Yedidia; Ruth Arnon
Journal:  Vaccine       Date:  2002-06-21       Impact factor: 3.641

2.  Immune response to cholera toxin epitope inserted in Salmonella flagellin.

Authors:  S M Newton; C O Jacob; B A Stocker
Journal:  Science       Date:  1989-04-07       Impact factor: 47.728

3.  Characterization of immune responses following intranasal immunization with the Mycobacterium bovis CFP-10 protein expressed by attenuated Salmonella typhimurium.

Authors:  H Zhang; K Wen; J Shen; S Geng; J Huang; Z Pan; X Jiao
Journal:  Scand J Immunol       Date:  2010-10       Impact factor: 3.487

4.  Method for the isolation of highly purified Salmonella flagellins.

Authors:  G F Ibrahim; G H Fleet; M J Lyons; R A Walker
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

5.  A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice.

Authors:  Margaret Morton; Helen S Garmory; Stuart D Perkins; Aisling M O'Dowd; Kate F Griffin; Arthur K Turner; Alice M Bennett; Richard W Titball
Journal:  Vaccine       Date:  2004-06-30       Impact factor: 3.641

6.  Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice.

Authors:  J McEwen; R Levi; R J Horwitz; R Arnon
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

7.  Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen.

Authors:  Haim Grosfeld; Sara Cohen; Tamar Bino; Yehuda Flashner; Raphael Ber; Emanuelle Mamroud; Chanoch Kronman; Avigdor Shafferman; Baruch Velan
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

8.  Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection.

Authors:  J L Flynn; M M Goldstein; K J Triebold; B Koller; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

9.  Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague.

Authors:  Helen S Garmory; Kate F Griffin; Katherine A Brown; Richard W Titball
Journal:  Vaccine       Date:  2003-06-20       Impact factor: 3.641

10.  A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague.

Authors:  Shixia Wang; Destin Heilman; Fangjun Liu; Theodore Giehl; Swati Joshi; Xiaoyun Huang; Te-hui Chou; Jon Goguen; Shan Lu
Journal:  Vaccine       Date:  2004-09-03       Impact factor: 3.641

View more
  4 in total

1.  Amino acids 89-96 of Salmonella typhimurium flagellin represent the major domain responsible for TLR5-independent adjuvanticity in the humoral immune response.

Authors:  Lei Zhang; Zhiming Pan; Xilong Kang; Yun Yang; Heekap Kang; Na Zhang; James M Rosati; Xinan Jiao
Journal:  Cell Mol Immunol       Date:  2014-09-08       Impact factor: 11.530

Review 2.  An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives.

Authors:  Alessio Facciolà; Giuseppa Visalli; Antonio Laganà; Angela Di Pietro
Journal:  Vaccines (Basel)       Date:  2022-05-22

Review 3.  The role of airway epithelial cells in response to mycobacteria infection.

Authors:  Yong Li; Yujiong Wang; Xiaoming Liu
Journal:  Clin Dev Immunol       Date:  2012-04-18

4.  Salt-Dependent Aggregation and Assembly of E coli-Expressed Ferritin.

Authors:  Wei Sun; Chengfeng Jiao; Yue Xiao; Luowei Wang; Cheng Yu; Jialin Liu; Yongli Yu; Liying Wang
Journal:  Dose Response       Date:  2016-02-26       Impact factor: 2.658

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.